Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
Hemab Therapeutics Holdings, Inc. execution reads as strong on proprietary earnings and initiative evidence.
Why it matters: Breakthrough Therapy Designation for sutacimig (Q2 FY2026).
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
COAG's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on COAG.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Hemab Therapeutics Holdings, Inc. (COAG) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
COAG's AI investment thesis
Upgrade to Premium for COAG's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$38.25
Market cap
$1.79B
Profitable
—
Net income
—
FY Sep 11, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Hemab Therapeutics Holdings, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Hemab Therapeutics Holdings, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.